Interview with Dr. Kyte at San Antonio Breast Cancer Symposium (SABCS) 2022
Here Dr. Jon Amund Kyte is talking about CAR-T therapy for solid tumors, Immunotherapy in breast cancer, and clinical trials.
In patients with metastatic triple-negative #BreastCancer, atezolizumab + anthracycline-based chemotherapy improves progression-free survival, including in PD-L1 negative disease.
@andreashr @GroupKyte @AmundJon @Oslounivsykehus @UniOslo_MED
Oppløftende prøvemetode mot brystkreft : – Ville ikke stått her uten den
Guri de Lange er en av 68 deltakere i pasientstudien til kreftforsker Jon Amund Kyte.
FOTO: LASR HÅKON PEDERSEN / NRK
Stort framskritt i norsk brystkreftforskning
Generalsekretær i Kreftforeningen, Ingrid Stenstadvold Ross (t.v.), i samtale med Guri de Lange, Andreas Røsseland Hage og Jon Amund Kyte.
Foto: Hanne Marie Molde
Data from the ALICE trial published in Nature Medicine
The randomized, placebo-controlled ALICE trial investigated the effect of treating metastatic triple-negative breast cancer patients with a combination of the immune checkpoint inhibitor atezolizumab and chemotherapy. Conclusions from this trial, led by Jon Amund Kyte at Oslo University Hospital (OUH), have now been published in Nature Medicine in an article titled “Atezolizumab plus anthracyclin-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase IIb ALICE trial”.
Guri de Lange (tv) thanks the researchers Andreas Hagen Røssevold and Jon Amund Kyte for allowing her to take part in the ALICE study and is thus alive and well today - four years after she relapsed. Photo: Hanne Marie Molde
Public Defence: Cand.med Elin Aamdal
will be defending the thesis: Click here
“Treating metastatic melanoma with ipilimumab – Clinical activity, health-related quality of life and combination with a telomerase peptide vaccine”
“Prevention and early detection strategies for melanoma”
Time and place: June 22, 2022 10:15 AM, Auditorium, Research building (K-building), The Norwegian Radium Hospital
First opponent: Lecturer Lars Ny, Sahlgrenska University Hospital
Second opponent: Professor Ingvild Vistad, University of Bergen
Third member and chair of the evaluation committee: Adjunct Professor Knut Jørgen Labori, University of Oslo
Chair of defence
Professor Ludvig A. Munthe, Faculty of Medicine, University of Oslo
Jon Amund Kyte, overlege dr.med., Seksjonsleder, Seksjon for utprøvende kreftbehandling, Forskningsgruppeleder, Seksjon for kreftimmunologi
Interviews with Pharma Boardroom
Oncologist Jon Amund Kyte shares some of the groundbreaking immunotherapy research that he and his team are conducting at Oslo University Hospital.
Webinar: Want to know more about breast cancer research?